Abstract Library

#2133 Clinicopathological Features of the High Grade Pancreatic Neuroendocrine Neoplasms

Introduction: The high grade pancreatic neuroendocrine neoplasms (PanNENs) include well-differentiated tumors (WD-NETs) with elevated proliferation and poorly differentiated carcinomas (PD-NECs).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Delektorskaya V, Solovieva O, Koslov N, Patyutko Y,

Keywords: neuroendocrine, pancreas, neoplasm, grade, survival,

#1467 iFiT: An Integrative Bioinformatics Platform for Biomarker and Target Discovery. A Case Study in Neuroendocrine Tumors

Introduction: iFiT (Ipsen Focused-on-new bIological enTities and biomarkers) is a Bioinformatics platform integrating systems biology functionalities together with semantic & logic-based artificial intelligence within a high-scale computing environment.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Tourlet S

Authors: Tourlet S, Scaerou F, Martin A, Thiagalingam A, Paty I,

Keywords: Targets iFiT,

#1083 NETs in Hospital Registry of Russian Cancer Center

Introduction: For the last 10-15 years NETS are a large area of clinical and scientific investigation.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Komarova L, Arion A, Patyutko Y, Gachramanov A,

Keywords: NETs, hospital registry,

#514 Cost-Effectiveness of Sunitinib in Patients (Pts) with Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET) in the Netherlands

Introduction: Sunitinib (SU) is an oral multitargeted tyrosine kinase inhibitor approved and reimbursed in the Netherlands for use in advanced/metastatic well-differentiated pNET.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Kansal A, Chao R, Patyna S, Scheijbeler H, Klok R,

Keywords: pancreatic NET, Sunitinib, overall survival, cost-effectiveness,